Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | SCD | O00767 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | PHGDH | O43175 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MASP2 | O00187 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21241962 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2SCDADORA3PARP1PHGDH | |
| SCHEMBL21224412 | 0.92 | SMN1; SMN2 (0.77) | SMN1; SMN2SCDADORA3PARP1PHGDH | |
| SCHEMBL21224414 | 0.92 | SMN1; SMN2 (0.77) | SMN1; SMN2SCDADORA3PARP1PHGDH | |
| SCHEMBL22971701 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2PARP1MAPTKDM4EALDH1A1 | |
| SCHEMBL21224175 | 0.83 | MEN1 (0.60) | SMN1; SMN2ADORA3PARP1MAPTKDM4E | |
| SCHEMBL21224713 | 0.83 | SCD (0.52) | SCDADORA3PARP1PHGDHMAPT | |
| SCHEMBL26673963 | 0.81 | SCD (0.74) | SCDADORA3PARP1PHGDHMAPT | |
| SCHEMBL21224486 | 0.81 | HTT (0.74) | SMN1; SMN2SCDADORA3PARP1MAPT | |
| SCHEMBL21224485 | 0.81 | HTT (0.74) | SMN1; SMN2SCDADORA3PARP1MAPT | |
| SCHEMBL21224205 | 0.80 | XIAP (0.65) | SMN1; SMN2SCDADORA3PARP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-02-11 | — | — | US | disclosed |
| CN-112153984-A | Compound and use thereof | 福宏治疗公司 | 2020-12-29 | — | — | CN | disclosed |
| WO-2019152437-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | SMN1; SMN2 40/4885SCD 3594/4885ADORA3 3993/4885 |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | SMN1; SMN2 40/4885SCD 3594/4885ADORA3 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.